TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19368505
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV7) given 3 months after transplantation
Study: 19368505
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV7) given 9 months after transplantation
Study: 16418785
Drug: Alendronate (ALN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (ALN), 5-10 mg/day
Study: 15288321
Drug: Azithromycin (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (4.0 g total over 4 weeks, 1000 mg weekly)
Study: 15288321
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg b.i.d. for 28 days)
Study: 8482456
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg three times a day, n = 57)
Study: 8482456
Drug: Propranolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (up to maximum tolerated dose, n = 61)
Study: 2446058
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 or 40 mg doses twice daily)
Study: 2446058
Drug: Ketanserin +
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin + Atenolol (100 mg/day)
Study: 2446058
Drug: Ketanserin +
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin + Hydrochlorothiazide (50 mg/day) + Amiloride (5 mg/day)
Study: 15963092
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 400 mg once daily
Study: 12906966
Drug: i.v.+s.c. enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.+s.c. enoxaparin treatment
Study: 12906966
Drug: s.c. alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. alone enoxaparin treatment
Study: 7066128
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 7.5 mg ml‐1 administered in sitting position
Study: 7066128
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 5 mg ml‐1 administered in horizontal position
Study: 7066128
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 7.5 mg ml‐1 in horizontal posture
Study: 7066128
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine 5 mg ml‐1 in horizontal posture
Study: 30260724
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.5% levobupivacaine applied at incision sites + 10 mL 0.5% levobupivacaine injected intraperitoneally and at trocar sites
Study: 30260724
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.5% ropivacaine at incision sites + 10 mL 0.5% ropivacaine injected intraperitoneally and at trocar sites
Study: 30260724
Drug: No peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peritoneal or local administration of local anesthetics (Control Group 1)
Study: 17560989
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy for cutaneous melanoma
Study: 15729204
Drug: Immunotherapy approaches
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy approaches including antibodies, peptides, or dendritic cell vaccines
Study: 9211625
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg s.c., bid and 1.5 mg/kg s.c. daily)
Study: 8433421
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (including enteric-coated aspirin and plain aspirin)
Study: 31664303
Drug: Piroxicam (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (200 mg)
Study: 25667217
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% (0.2 mL)
Study: 25667217
Drug: Decongestant only
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant only
Study: 24967526
Drug: Drug Adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Adherence Work-up (DRAW) tool
Study: 11681004
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (combination therapy with mitomycin C, 5-fluorouracil, and nonspecific immunomodulators such as PSK and OK-432)
Study: 11681004
Drug: Biochemical modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical modulators (low-dose FP and S 1)
Study: 7664193
Drug: Memory training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory training (weekly group sessions of 60 min for 1 year)
Study: 2718782
Drug: Calcium-25-OHD (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-25-OHD (1200 mg/day of calcium as calcium carbonate and 40 micrograms/day of 25-OHD)
Study: 2718782
Drug: Calcium-placebo (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-placebo (1200 mg/day of calcium plus placebo)
Study: 1097097
Drug: Daunorubicin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (25 mg/m given intravenously) + Methotrexate (25 mg/m/dose given orally twice weekly)
Study: 1097097
Drug: Methotrexate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25 mg/m/dose given orally twice weekly)
Study: 21375762
Drug: Chlorthalidone 12.5
Normalized name: chlorthalidone 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg plus amiloride 2.5 mg
Study: 19713967
Drug: Active HHQ-reduced
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active HHQ-reduced coffee (300 mg chlorogenic acids per 184 ml of coffee)
Study: 19713967
Drug: Placebo HHQ-reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HHQ-reduced coffee (0 mg chlorogenic acids per 184 ml of coffee)
Study: 17597089
Drug: ECC rinse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECC rinse with unfractionated heparin (UFH)
Study: 17597089
Drug: ECC rinse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECC rinse without unfractionated heparin (UFH)
Study: 8002117
Drug: Fluid ingestion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid ingestion (F) - 400 ml bolus of 20 mmol/l NaCl immediately before exercise and 120 ml feedings every 10 min during the first 50 min of exercise.
Study: 29212509
Drug: Low-dose, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, high-frequency (LDHF) training
Study: 25919644
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of finasteride (1.0 mg)
Study: 16087660
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture (Vamin 18 g N/l)
Study: 1725539
Drug: Diltiazem (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (sustained-release or conventional tablets)
Study: 1725539
Drug: Diltiazem and
Normalized name: Diltiazem and enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem and captopril (combination therapy)
Study: 1725539
Drug: Diltiazem with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem with hydrochlorothiazide or atenolol (combination therapy)
Study: 1725539
Drug: Diltiazem (monotherapy)
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem (monotherapy)
Study: 31567875
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) topic
Study: 31567875
Drug: Self-administered learning
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered learning modules
Study: 29167052
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (CBT) for SHA, 12 weeks
Study: 25749132
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) program, 6-week duration, 6 lessons using a Manga story
Study: 23727057
Drug: Microdose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose of (14)C‐tolbutamide (100 μg)
Study: 19222929
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of antimicrobial therapy (2 weeks intravenous ceftriaxone and 2 weeks oral ciprofloxacin)
Study: 19222929
Drug: Chloramphenicol or
Normalized name: chloramphenicol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol or ceftriaxone treatment (duration not specified)
Study: 12742869
Drug: Present-centered comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered comparison treatment
Study: 12742869
Drug: Trauma-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused group therapy (adequate dose)
Study: 8866262
Drug: Bonding agent
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonding agent and light‐cured composite resin
Study: 8866262
Drug: Conventional glass‐ionomer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glass‐ionomer, bonding agent and light‐cured composite resin
Study: 8866262
Drug: Light‐cured glass‐ionomer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light‐cured glass‐ionomer, extended 0.3 mm short of the enamel margin, bonding agent and light‐cured composite resin
Study: 8866262
Drug: Light‐cured glass‐ionomer,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light‐cured glass‐ionomer, extended 1 mm short of the enamel margin, bonding agent and light‐cured composite resin
Study: 26930607
Drug: GSK1070806 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1070806 0.25 mg/kg
Study: 26930607
Drug: GSK1070806 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1070806 5 mg/kg
Study: 24456510
Drug: Weekly monetary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly monetary incentives for fitness-center attendance during fall semester
Study: 22198821
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera leaf gel (300 mg capsule every 12 hours for 2 months)
Study: 20954664
Drug: Viscoseal (hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoseal (hyaluronic acid) injection
Study: 18203570
Drug: INSIGHT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: INSIGHT therapy
Study: 16355440
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of rhubarb extract (50 mg.kg(‐1))
Study: 16355440
Drug: Retention enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retention enema administration of rhubarb extract (50 mg.kg(‐1))
Study: 16355440
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and retention enema administration of rhubarb extract
Study: 11867397
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine (25 mg in 8.3% glucose)
Study: 11867397
Drug: Plain ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain ropivacaine (25 mg)
Study: 7474676
Drug: Naloxone 0.1
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.1 mg/kg i.v. bolus, followed by 0.1 mg/kg/hr
Study: 7474676
Drug: HOI during
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HOI during concomitant naloxone administration
Study: 28137634
Drug: Metoclopramide administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide administration in patients with NLR greater than 2 (group II)
Study: 28137634
Drug: Metoclopramide administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide administration in patients with NLR less than 2 (group I)
Study: 24026159
Drug: Chiropractic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic therapy
Study: 19708000
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg
Study: 11710710
Drug: diacerein (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diacerein (50 mg twice a day)
Study: 8331204
Drug: Vigabatrin single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin single oral doses (0.5 to 4.0 g)
Study: 8331204
Drug: Vigabatrin multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin multiple oral doses (0.5 to 2.0 g every 12 hours)
Study: 29751001
Drug: Ixekizumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (160 mg starting dose followed by 80 mg every 2 weeks, then 80 mg every 4 weeks during extension)
Study: 24122840
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with atenolol and HCTZ
Study: 20879647
Drug: Standard reverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reverse L-flap (RLF)
Study: 12093440
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition or fiber‐free enteral nutrition (group A)
Study: 8787257
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthetic (propofol for induction followed by propofol infusion)
Study: 8787257
Drug: Combined intravenous‐inhalational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous‐inhalational anaesthetic (propofol with isoflurane in oxygen‐enriched air)
Study: 2025840
Drug: Local irradiation
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local irradiation only (L‐XRT)
Study: 2025840
Drug: Local radiation
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local radiation doses over 4500 cGy
Study: 2025840
Drug: Local radiation
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local radiation doses less than 4500 cGy
Study: 6465150
Drug: Decentralized unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decentralized unit dose system (control)
Study: 24813374
Drug: Long-acting dexmethylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting dexmethylphenidate (D-MPH) at doses of 10-20 mg
Study: 24813374
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts (MAS) at doses of 10-20 mg
Study: 23123106
Drug: AH-adjuvanted PcpA
Normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH-adjuvanted PcpA (25 μg)
Study: 23123106
Drug: AH-adjuvanted PhtD-PcpA
Normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH-adjuvanted PhtD-PcpA (10, 25, or 50 μg each)
Study: 23123106
Drug: Unadjuvanted PhtD-PcpA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted PhtD-PcpA (25 μg each)
Study: 23123106
Drug: AH-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH-adjuvanted vaccines
Study: 19195328
Drug: lamivudine plus
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine plus pegylated interferon‐alpha2b combination therapy for 24 weeks
Study: 19195328
Drug: lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine monotherapy for 28 weeks
Study: 15787659
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mixture plus metformin
Study: 20649032
Drug: Glargine plus
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine plus metformin
Study: 12453070
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg IVIG
Study: 12453070
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg IVIG
Study: 2248072
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 to 328 mg in first study; 294-408 mg in second study)
Study: 2248072
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 to 96 mg in first study; 95-129 mg in second study)
Study: 7364977
Drug: Corticosteroid antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid antimicrobial cream with fluocinonide 0.05%
Study: 7364977
Drug: Corticosteroid antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid antimicrobial cream with triamcinolone 0.1%
Study: 7364977
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing only antimicrobial agents
Study: 31835476
Drug: Fibre-enriched orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-enriched orange juice (1.4 g/100 mL of citrus fibre)
Study: 26163858
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education with exercise therapy
Study: 26163858
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education without exercise therapy
Study: 3294615
Drug: Cefamandole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (15 mg/kg)
Study: 3294615
Drug: Tobramycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1.5 mg/kg)
Study: 3294615
Drug: Tobramycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (3 mg/kg)
Study: 3294615
Drug: Cefamandole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (15 mg/kg) + Tobramycin (1.5 mg/kg)
Study: 3294615
Drug: Cefamandole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (15 mg/kg) + Tobramycin (3 mg/kg)
Study: 30431426
Drug: FS Spiromax
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS Spiromax 500/50 µg
Study: 30431426
Drug: Seretide Accuhaler
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seretide Accuhaler 50/500 µg
Study: 30431426
Drug: FS Spiromax
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS Spiromax 500/50 µg with charcoal block
Study: 30431426
Drug: Seretide Accuhaler
Normalized name: seractide
DrugBank: Seractide acetate (DB09334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seretide Accuhaler 50/500 µg with charcoal block
Study: 14699543
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravenous antibiotics)
Study: 11721154
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium reduced diet (300 mg/24 h) for 4 weeks after a 3-week run-in period (dietary calcium content 700-1,000 mg/24 h)
Study: 9012545
Drug: Sizofiran (SPG)
Normalized name: Sizofiran
DrugBank: Sizofiran (DB13128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sizofiran (SPG) administration
Study: 3891497
Drug: Heidelberg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heidelberg capsule after a 4-ml/kg liquid fatty meal
Study: 3891497
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal (200 ml of diluted light cream)
Study: 27421057
Drug: Combination HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV prevention package (including household‐based HIV counselling and testing and anti‐retroviral treatment eligibility regardless of CD4‐count)
Study: 24645793
Drug: Avenanthramide (AVA)
Normalized name: AVENANTHRAMIDES
DrugBank: Avenanthramides (DB14743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenanthramide (AVA) supplementation (9.2 mg AVA per day)
Study: 23235391
Drug: Low-dose erythropoietin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose erythropoietin stimulating agent (ESA) treatment
Study: 23235391
Drug: No erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No erythropoietin stimulating agent (no-ESA) treatment
Study: 19896252
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100ml of a fermented milk product
Study: 12435170
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U weekly (increased to 60,000 U weekly for inadequate response)
Study: 30156436
Drug: MEC (DigeZyme®)
Normalized name: CATHETER,EXTERNAL MALE QIVI MEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEC (DigeZyme®) 50 mg, TID for 60 days
Study: 19717722
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily from days 1 to 5 with 100 mg lamotrigine on day 4
Study: 19717722
Drug: Lamotrigine 100
Normalized name: lamotrigine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 100 mg alone on day 32
Study: 11497195
Drug: Omapatrilat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (10 or 20 mg, titrated to 20 or 40 mg) plus 25 mg of HCTZ
Study: 11497195
Drug: Omapatrilat (20/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (20/40 mg) plus 25 mg of HCTZ
Study: 11497195
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 25 mg of HCTZ
Study: 2938394
Drug: Alfentanil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (50 micrograms/kg) and atracurium (0.5 mg/kg)